PDS Biotechnology Says Its Key Opinion Leader Roundtable On Addressing Current And Future Treatments For Recurrent/Metastatic Human Papillomavirus-positive Head And Neck Squamous Cell Carcinoma And The Potential Application Of PDS0101 Will Happen On Oct3
Portfolio Pulse from Benzinga Newsdesk
PDS Biotechnology has announced that its Key Opinion Leader Roundtable on addressing current and future treatments for recurrent/metastatic human papillomavirus-positive head and neck squamous cell carcinoma and the potential application of PDS0101 will take place on October 3. The event was originally scheduled for September 27, 2023.
September 25, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
PDS Biotechnology's rescheduling of its Key Opinion Leader Roundtable could potentially impact the company's stock. The event will discuss the potential application of PDS0101, a key product in their pipeline.
The rescheduling of the roundtable discussion could potentially impact PDS Biotechnology's stock as it pertains to the potential application of PDS0101, a key product in their pipeline. However, the impact is uncertain as it depends on the outcome of the discussion and the market's reaction to it.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100